# EDGAR Filing Document

**Accession Number:** 0001039466
**File Stem:** 0001185185-23-000220
**Filing Date:** 2023-3
**Character Count:** 5275
**Document Hash:** 7fd2cbeefb1ede1b18dffb45ef555e9e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-23-000220.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001185185-23-000220

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NovAccess Global Inc.
- **CENTRAL INDEX KEY:** 0001039466
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 841384159
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29621
- **FILM NUMBER:** 23737688

**BUSINESS ADDRESS:**
- **STREET 1:** 8584 E. WASHINGTON STREET, NO. 127
- **CITY:** CHAGRIN FALLS
- **STATE:** OH
- **ZIP:** 44023
- **BUSINESS PHONE:** (213) 642-9268

**MAIL ADDRESS:**
- **STREET 1:** 8584 E. WASHINGTON STREET, NO. 127
- **CITY:** CHAGRIN FALLS
- **STATE:** OH
- **ZIP:** 44023

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XSUNX INC
- **DATE OF NAME CHANGE:** 20031001

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SUN RIVER MINING INC
- **DATE OF NAME CHANGE:** 20000218

?xml version="1.0" encoding="ASCII"? novaccess20230315_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

<u>**March 13, 2023**</u>

(Date of earliest event reported)

<u>**NovAccess Global Inc.**</u>

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| <u>**Colorado**</u> | <u>**000-29621**</u> | <u>**84-1384159**</u> |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| |
|:---|
| <u>**8584 E. Washington Street, No. 127, Chagrin Falls, Ohio 44023**</u> |
| (Address of principal executive offices) (Zip Code) |

---

<u>**(213) 642-9268**</u>

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 13, 2023, NovAccess Global Inc. ("NovAccess," the "company" or "we") entered into non-qualified stock option agreements and granted vested ten-year options to purchase shares of the company's common stock for $0.175 a share, the closing price on the grant date. We issued options to purchase a total of 3,542,857 shares as follows: (a) 857,143 to each of our independent directors, Jason M. Anderson and John A. Cassarini; (b) 428,571 to Neil J. Laird, our chief executive officer, and 571,429 to Dr. Christopher Wheeler, president of our StemVax Therapeutics subsidiary; (c) 57,143 to each of our scientific advisory board members; and (d) the remaining 542,857 to staff members and other officers.

**Item 3.02 Unregistered Sales of Equity Securities.**

The disclosure included under Item 1.01 above is incorporated by reference to this Item 3.02. The issuances of the stock options to our independent directors, officers, scientific advisory board members, and staff were exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | **NovAccess Global Inc.** |
| Dated March 16, 2023&nbsp;&nbsp;&nbsp;&nbsp; | *<u>/s/ Dwain K. Irvin</u>* <br> By Dwain K. Irvin, Chief Executive Officer |

---

&nbsp;&nbsp;&nbsp;&nbsp;